ReviewDrugs2020
Pharmacokinetics and Pharmacodynamics of Posaconazole.
Review in Drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 3 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- Factors affecting posaconazole plasma concentrations: a meta-analysis and systematic review.Frontiers in pharmacology · 2024Pooled it
- Comparison of antifungal drugs in the treatment of invasive pulmonary aspergillosis: a systematic review and network meta-analysis.Frontiers in microbiology · 2024Pooled it
- Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Frontiers in cellular and infection microbiology · 2022Pooled it
- Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial.Intensive care medicine · 2021Trial
- From Chemistry to Clinic: Amorphous Solid-State Modification Strategies for Oral Azole Antifungals.ACS omega · 2026Review
- Cutaneous Mucormycosis Clinically Mimicking Necrotizing Fasciitis in a Patient Without Active Immunosuppression.Clinical case reports · 2026Article
- Analysis of interactions between posaconazole/voriconazole and venetoclax.Antimicrobial agents and chemotherapy · 2026Article
- Alginate-Polymethacrylate Hybrid Microparticles as Multi-Unit Enteric Drug Carriers for Posaconazole.Pharmaceutics · 2026Article
- Comparing Efficacy and Safety of Itraconazole Solution Versus Posaconazole for Antifungal Prophylaxis After Heart Transplant.Open forum infectious diseases · 2026Article
- In Vitro Activities of Five Antifungal Drugs Against Conidia and Sclerotic Cells of Chromoblastomycosis Agent Fonsecaea spp.Microbiology and immunology · 2026Article
- Emerging Applications of Triazole Antifungal Drugs.International journal of molecular sciences · 2026Review
- Urinary tract infection caused by rare yeastFrontiers in immunology · 2026Review
- Case Report: A diabetic ketoacidosis in adolescents complicated with rhino-orbital-cerebral mucormycosis.Frontiers in medicine · 2026Article
- Isavuconazole: Need for therapeutic drug monitoring and CYP polymorphism testing.Medical mycology case reports · 2025Article
- Review
- Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations.British journal of clinical pharmacology · 2025Observational
- Adjunctive use of posaconazole, hyperbaric oxygen therapy, and methylene blue for COVID-19-associated mucormycosis.Oral and maxillofacial surgery · 2025Observational
- Theoretical insight and molecular recognition of fluconazole molecularly imprinted polymers: a combined computational and experimental analysis.RSC advances · 2025Article
- Gene Polymorphisms Play an Important Role in the Drug Interaction Between Posaconazole and Tacrolimus in Renal Transplant Patients.Therapeutic drug monitoring · 2025Article
- QSPR and QSTR analysis to explore pharmacokinetic and toxicity properties of antifungal drugs through topological descriptors.Scientific reports · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posaconazole is typically used for preventing invasive yeast and mold infections such as invasive aspergillosis in high-risk immunocompromised patients. The oral suspension was the first released formulation and many pharmacokinetic and pharmacodynamic studies of this formulation have been published. Erratic absorption profiles associated with this formulation were widely reported. Posaconazole exposure was found to be significantly influenced by food and many gastrointestinal conditions, including pH and motility. As a result, low posaconazole plasma concentrations were obtained in large groups of patients. These issues of erratic absorption urged the development of the subsequently marketed delayed-release tablet, which proved to be associated with higher and more stable exposure profiles. Shortly thereafter, an intravenous formulation was released for patients who are not able to take oral formulations. Both new formulations require a loading dose on day 1 to achieve high posaconazole concentrations more quickly, which was not possible with the oral suspension. So far, there appears to be no evidence of increased toxicity correlated to the higher posaconazole exposure achieved with the regimen for these formulations. The higher systemic availability of posaconazole for the delayed-release tablet and intravenous formulation have resulted in these two formulations being preferable for both prophylaxis and treatment of invasive fungal disease. This review aimed to integrate the current knowledge on posaconazole pharmacokinetics, pharmacodynamics, major toxicity, existing resistance, clinical experience in special populations, and new therapeutic strategies in order to get a clear understanding of the clinical use of this drug.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.